Vitamin D compounds

• US 4,804,502 A
• Filed: 01/20/1988
• Issued: 02/14/1989
• Est. Priority Date: 01/20/1988
• Status: Expired due to Fees

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Partridge, John J., Uskokovic, Milan R., Shiuey, Shian-Jan, Baggiolini, Enrico G., Truitt, Gary A.
• Primary Examiner(s): Lone, Werren B.
• Application Number:
  US07/145,867
• Time in Patent Office: 391 Days
• Field of Search: 568/816, 568/817, 568/832, 568/834, 568/838, 260/397.2
• US Class Current: 514/167
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 309/00 Sulfonic acids; Halides, esters, or anhydrides thereof
• CPC Class Codes: C07C 35/32 the condensed ring system being a (4.3.0) system, e.g. indenols
• CPC Class Codes: C07C 401/00 Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• CPC Class Codes: C07C 45/305 with halogenochromate reagents, e.g. pyridinium chlorochromate
• CPC Class Codes: C07C 49/743 having unsaturation outside the rings, e.g. humulones, lupulones
• CPC Class Codes: C07F 7/1804 Compounds having Si-O-C linkages Si-O-acyl linkages C07F7/1896

Abstract

Compounds of the formula ##STR1## wherein R₁ is hydrogen or hydroxy and R₂ is hydrogen or fluorine are described. The compounds of formula I are useful as agents in the treatment of disease states characterized by metabolic calcium deficiencies. Examplary of such disease states are osteoporosis and renal osteodystrophy.

Claims

1. A compound of the formula ##STR10## wherein R₁ is hydrogen or hydroxy and R₂ is hydrogen or fluorine.

2. A compound in accordance with claim 1, wherein R₂ is fluorine.

3. The compound in accordance with claim 2, 1α

,25-dihydroxy-23-yne-26,26,26,27,27,27-hexafluorocholecalciferol.

4. The compound in accordance with claim 2, 25-hydroxy-23-yne-26,26,26,27,27,27-hexafluorocholecalciferol.

5. A compound in accordance with claim 1, wherein R₂ is hydrogen.

6. The compound in accordance with claim 5, 1α

,25-dihydroxy-23-yne-cholecalciferol.

7. The compound in accordance with claim 5, 25-hydroxy-23-yne-cholecalciferol.

8. A composition comprising a pharmaceutically effective amount of a compound of the formula ##STR11## wherein R₁ is hydrogen or hydroxy and R₂ is hydrogen or fluorine, and

a pharmaceutically acceptable carrier material.

9. A composition in accordance with claim 8 wherein R₂ is fluorine.

10. A composition in accordance with claim 9, wherein the compound of formula I is 1α

,25-dihydroxy-23-yne-26,26,26,27,27,27-hexafluorocholecalciferol.

11. A method for treating disease states characterized by metabolic calcium deficiencies which comprises administering an effective amount of a compound of the formula ##STR12## wherein R₁ is hydrogen or hydroxy and R₂ is hydrogen or fluorine.

12. A method in accordance with claim 11, wherein the disease state characterized by metabolic calcium deficiency is osteoporosis.

13. A method in accordance with claim 12, wherein R₂ is fluorine.

14. A method in accordance with claim 13, wherein the compound of formula I is 1α

,25-dihydroxy-23-yne-26,26,26,27,27,27-hexafluorocholecalciferol.

15. A method in accordance with claim 11, wherein the compound of formula I is administered in a dosage of from about 0.1 μ

g to about 2 μ

g.